Clinical Trial

Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation

Study acronym: PRIME
Suspended
View on ClinicalTrials.gov →
Why the trial stopped
As a part of planned reassessment for the current period, a decision has been made to prioritize, optimize, and reallocate resources. As a result, enrollment and other study activities have been temporarily halted.
Summary
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-27; most recent amendment 2026-06-25.
Status change: Recruiting → Suspended 2026-05-27
Trial Details
NCT Number NCT07146113
Lead Sponsor AstraZeneca
Conditions Prostate Cancer
Enrollment 400 participants
Start Date 2025-06-30
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-26